Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies

Chimeric antigen receptor (CAR)-T cell therapy has transformed pediatric oncology by producing high remission rates and potent effects in CD19+ B-cell malignancies. This scenario is ideal as CD19 expression is homogeneous and human blood provides a favorable environment for CAR-T cells to thrive and...

Full description

Bibliographic Details
Main Authors: Yingjuan J. Lu, Haiyan Chu, Leroy W. Wheeler, Melissa Nelson, Elaine Westrick, James F. Matthaei, Ian I. Cardle, Adam Johnson, Joshua Gustafson, Nikki Parker, Marilynn Vetzel, Le-Cun Xu, Emilia Z. Wang, Michael C. Jensen, Patrick J. Klein, Philip S. Low, Christopher P. Leamon
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
folate receptor
chimeric antigen receptor
CAR-T adaptor molecule
acute myeloid leukemia
osteosarcoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00151/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00151/full

Similar Items